Search
Summit Therapeutics Inc
SMMTAdd to Watchlist
17.605USD
+0.475+2.77%
Close 09-04 16:00（ET）
13.96BMarket Cap
LossP/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
+2.77%
5 Days
+28.22%
1 Month
+30.12%
6 Months
+17.84%
Year to Date
+0.66%
1 Year
-32.24%
Key Figures
16.935Open
17.630High
647.82KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.08%Turnover Ratio
17.130Prev. Close
16.800Low
11.25MTurnover
LossP/E Static
22.16P/B
0.00%Div Yield TTM
-233.81%ROA
29.23052wk High
0.10Volume Ratio
-221.31MNet Profit
793.12MShares
-1.6029EPS TTM
-1.31Beta
-270.95%ROE
12.07052wk Low
4.79%Amplitude
100.00%Gross Margin
13.96BMarket Cap
-0.30Reward/Risk
4.51%Risk Rate
Summit Therapeutics Inc Stock (SMMT) Moved Up by 8.95% on Aug 26: Drivers Behind the Movement
• Summit Therapeutics shares rose following positive Phase 3 trial results for ivonescimab. • The HARMONi-GI1 study met its primary overall survival endpoint in biliary tract cancer. • Summit reports zero annual revenue and a net loss of $1.08 billion.
TradingKeyWed, Aug 26
Summit Therapeutics Inc Stock (SMMT) Moved Up by 12.03% on Apr 16: Drivers Behind the Movement
• Analyst ratings and price targets suggest significant upside potential. • FDA accepted BLA for ivonescimab, with a PDUFA date in November 2026. • Institutional investors increased holdings, indicating growing conviction.
TradingKeyThu, Apr 16
Summit Therapeutics Inc's Score
-0.09vs previous score
Forecast7.56
Financial Health6.80
Technical5.72
Valuation Dimensions8.62
Institutional Confidence3.00
Risk Assessment4.67
Media Coverage
Coverage Level
Very Low
Very High
No data
Analyst Rating
Summit Therapeutics Inc Technical Analysis
Technical Indicators
Buy
Summary
Buy
Moving Average
Strong buy
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
-0.28/-0.28
Revenue / Forecast
--/0.00
Summit Therapeutics Inc Profile
SectorBiotechnology & Medical Research
Ticker SymbolSMMT
Number of employees159
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Duggan (Robert William) | 73.45% |
| Baker Bros. Advisors LP | 4.69% |
| Zanganeh (Mahkam) | 4.64% |
| Xia (Yu) | 4.13% |
| Shareholder Types | Proportion |
|---|---|
| Individual Investor | 82.64% |
| Investment Advisor | 7.18% |
| Hedge Fund | 5.75% |
| Investment Advisor/Hedge Fund | 2.40% |
Related Instruments
-0.88%
-1.15%
-1.26%
-1.44%
-1.32%
-1.90%
-1.55%
-0.15%
-1.25%
-1.92%
-2.12%
-1.87%
-0.20%
-1.45%
-1.93%
-1.87%
-1.93%
-1.39%
-2.23%
-0.58%Popular Instruments
53223.600
-424.100 (-0.79%)
29485.000
+28.400 (+0.10%)
7707.500
-33.100 (-0.43%)
14652.000
+73.000 (+0.50%)
65807.000
+1147.000 (+1.77%)
6397.800
+19.300 (+0.30%)
90.424
-0.597 (-0.66%)
319.970
-8.240 (-2.51%)
230.360
+1.910 (+0.84%)
4429.740
-42.920 (-0.96%)
FAQs
What is the current price of Summit Therapeutics Inc (SMMT)?
The current price of Summit Therapeutics Inc (SMMT) is 17.60.
What is the symbol of Summit Therapeutics Inc?
The ticker symbol of Summit Therapeutics Inc is SMMT.
What is the 52-week high of Summit Therapeutics Inc?
The 52-week high of Summit Therapeutics Inc is 29.23.
What is the 52-week low of Summit Therapeutics Inc?
The 52-week low of Summit Therapeutics Inc is 12.07.
What is the market capitalization of Summit Therapeutics Inc?
The market capitalization of Summit Therapeutics Inc is 13.96B.
Is Summit Therapeutics Inc (SMMT) currently rated as Buy, Hold, or Sell?
According to analysts, Summit Therapeutics Inc (SMMT) has an overall rating of Buy, with a price target of 28.35.
What is the Earnings Per Share (EPS TTM) of Summit Therapeutics Inc (SMMT)?
The Earnings Per Share (EPS TTM) of Summit Therapeutics Inc (SMMT) is -1.60.